8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Feb 25, 2026·SEC
Material company update
Jan 30, 2026·SEC
Immunocore Holdings plc(IMCR)Earnings, Financials & Key Ratios
IMCR•NASDAQ
Price updated Jun 19, 2026
AboutImmunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Show more
- Revenue$298M+20.0%
- EBITDA-$31M+40.8%
- Net Income-$26M+35.3%
- EPS (Diluted)-0.53+48.0%
- Gross Margin97.91%+0.2%
- EBITDA Margin-10.52%+50.7%
- Operating Margin-11.34%+50.0%
- Net Margin-8.88%+46.0%
- ROE-7.12%+43.0%
IMCR Key Insights
Immunocore Holdings plc (IMCR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 18.6%
- ✓Strong 5Y sales CAGR of 58.1%
✗Weaknesses
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when IMCR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IMCR Price & Volume
Immunocore Holdings plc (IMCR) stock price & volume — 10-year historical chart
Loading chart...
IMCR Growth Metrics
Immunocore Holdings plc (IMCR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years33.2%
5 Years58.11%
3 Years27.3%
TTM15.64%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM12.98%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM11.2%
Return on Capital
10 Years-34.23%
5 Years-18.54%
3 Years-8.62%
Last Year-4.17%
IMCR Recent Earnings
Immunocore Holdings plc (IMCR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.25+196.2%
$0.26
Rev
$145M-0.3%
$145M
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$0.60-114.3%
$0.28
Rev
$140M-3.1%
$144M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.02+105.2%
$0.30
Rev
$104M-27.1%
$142M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.20+4.8%
$0.21
Rev
$134M+0.1%
$134M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.25vs $0.26+196.2% | $145Mvs $145M-0.3% |
| Q1 2026 | Feb 25, 2026 | $0.60vs $0.28-114.3% | $140Mvs $144M-3.1% |
| Q4 2025 | Nov 6, 2025 | $0.02vs $0.30+105.2% | $104Mvs $142M-27.1% |
| Q3 2025 | Aug 7, 2025 | $0.20vs $0.21+4.8% | $134Mvs $134M+0.1% |
Based on last 12 quarters of dataView full earnings history →
IMCR Peer Comparison
Immunocore Holdings plc (IMCR) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 MGNX | 262.52M | 4.13 | -3.50 | 0.78% | -44.79% | -147.8% | 1.92 | |
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 ADCT | 138.64M | 1.09 | -0.97 | 14.85% | -173.02% | |||
 GILD | 153.66B | 123.76 | 18.25 | 2.39% | 30.99% | 42.33% | 1.09 | |
 EXEL | 13.19B | 51.91 | 18.67 | 6.98% | 35.08% | 40.21% | 0.08 |
Compare IMCR vs Peers
Immunocore Holdings plc (IMCR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IMCR Income Statement
Immunocore Holdings plc (IMCR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 19.17M | 23.65M | 25.67M | 30.11M | 27.04M | 144.23M | 197.39M | 247.98M | 297.57M | 385.76M |
Revenue Growth % | -5.19% | 23.42% | 8.52% | 17.32% | -10.19% | 433.32% | 36.85% | 25.63% | 20% | 15.64% |
Cost of Goods Sold | 0 | 0 | 99.99M | 74.81M | 0 | 5.29M | 820.63K | 5.54M | 6.21M | 4.61M |
COGS % of Revenue | - | - | 389.54% | 248.42% | - | 3.67% | 0.42% | 2.24% | 2.09% | - |
Gross Profit | 19.17M▲ 0% | 23.65M▲ 23.4% | -74.32M▼ 414.2% | -44.7M▲ 39.9% | 27.04M▲ 160.5% | 138.94M▲ 413.7% | 196.57M▲ 41.5% | 242.44M▲ 23.3% | 291.36M▲ 20.2% | 381.15M▲ 0% |
Gross Margin % | 100% | 100% | -289.54% | -148.42% | 100% | 96.33% | 99.58% | 97.76% | 97.91% | 98.81% |
Gross Profit Growth % | -5.19% | 23.42% | -414.2% | 39.86% | 160.51% | 413.74% | 41.47% | 23.34% | 20.18% | - |
Operating Expenses | 109.94M | 117.73M | 44M | 41.5M | 156.46M | 181.71M | 243.77M | 298.77M | 325.09M | 410.51M |
OpEx % of Revenue | 573.67% | 497.72% | 171.41% | 137.8% | 578.53% | 125.99% | 123.5% | 120.48% | 109.25% | - |
Selling, General & Admin | 29.22M | 34.16M | 44.18M | 45.74M | 82.15M | 0 | 114.35M | 121.17M | 120.62M | 151.41M |
SG&A % of Revenue | 152.47% | 144.4% | 172.13% | 151.89% | 303.76% | - | 57.93% | 48.86% | 40.54% | - |
Research & Development | 81.13M | 83.58M | 99.99M | 74.81M | 74.31M | 84.31M | 129.42M | 177.44M | 204.47M | 259.11M |
R&D % of Revenue | 423.34% | 353.32% | 389.54% | 248.42% | 274.77% | 58.45% | 65.57% | 71.55% | 68.71% | - |
Other Operating Expenses | -411.37K | 0 | -100.18M | -79.05M | 0 | 97.4M | 0 | 0 | 0 | 0 |
Operating Income | -90.78M▲ 0% | -93.45M▼ 2.9% | -118.32M▼ 26.6% | -86.19M▲ 27.2% | -129.42M▼ 50.1% | -42.77M▲ 66.9% | -47.2M▼ 10.4% | -56.28M▼ 19.2% | -33.74M▲ 40.1% | -29.36M▲ 0% |
Operating Margin % | -473.67% | -395.09% | -460.95% | -286.22% | -478.53% | -29.66% | -23.91% | -22.7% | -11.34% | -7.61% |
Operating Income Growth % | -127.66% | -2.95% | -26.61% | 27.15% | -50.15% | 66.95% | -10.36% | -19.23% | 40.05% | - |
EBITDA | -85.53M | -86.75M | -111.56M | -79.75M | -123.79M | -38.36M | -43.97M | -52.92M | -31.31M | -27.16M |
EBITDA Margin % | -446.26% | -366.74% | -434.61% | -264.82% | -457.72% | -26.6% | -22.27% | -21.34% | -10.52% | -7.04% |
EBITDA Growth % | -133.86% | -1.43% | -28.6% | 28.52% | -55.23% | 69.01% | -14.61% | -20.37% | 40.84% | 37.61% |
D&A (Non-Cash Add-back) | 5.25M | 6.71M | 6.76M | 6.45M | 5.63M | 4.41M | 3.24M | 3.36M | 2.43M | 2.2M |
EBIT | -90.78M | -93.45M | -118.32M | -88.83M | -129.21M | -42.77M | -44.11M | -41.86M | -2.04M | -5.2M |
Net Interest Income | 703.1K | -20K | -2.4M | -2.4M | -5.51M | -1.65M | 10.15M | 6.77M | 4.31M | 3.17M |
Interest Income | 0 | 822K | 1.4M | 706K | 65K | 3.76M | 14.23M | 25.62M | 16.48M | 15.77M |
Interest Expense | 0 | 842K | 3.8M | 3.11M | 5.57M | 5.41M | 4.08M | 18.84M | 12.17M | 6.13M |
Other Income/Expense | 3.76M | 5.28M | 36.65M | -1.17M | -3.92M | 8.95M | -982.07K | 14.01M | 19.53M | 21.54M |
Pretax Income | -87.02M▲ 0% | -88.18M▼ 1.3% | -81.67M▲ 7.4% | -87.36M▼ 7.0% | -133.34M▼ 52.6% | -33.82M▲ 74.6% | -48.19M▼ 42.5% | -42.32M▲ 12.2% | -14.21M▲ 66.4% | -7.82M▲ 0% |
Pretax Margin % | -454.06% | -372.78% | -318.18% | -290.1% | -493.04% | -23.45% | -24.41% | -17.07% | -4.77% | -2.03% |
Income Tax | 21.26M | -16.55M | 22.26M | -13.27M | 111.19K | 9.65M | -4.43M | -1.48M | 12.21M | 10.4M |
Effective Tax Rate % | -24.43% | 18.77% | -27.25% | 15.19% | -0.08% | -28.52% | 9.2% | 3.49% | -85.94% | -132.9% |
Net Income | -65.76M▲ 0% | -71.63M▼ 8.9% | -103.93M▼ 45.1% | -74.09M▲ 28.7% | -133.45M▼ 80.1% | -43.46M▲ 67.4% | -43.75M▼ 0.7% | -40.81M▲ 6.7% | -26.42M▲ 35.3% | -18.82M▲ 0% |
Net Margin % | -343.13% | -302.82% | -404.89% | -246.04% | -493.45% | -30.13% | -22.17% | -16.45% | -8.88% | -4.88% |
Net Income Growth % | -131.54% | -8.93% | -45.09% | 28.71% | -80.11% | 67.43% | -0.66% | 6.73% | 35.26% | 12.98% |
Net Income (Continuing) | -65.76M | -71.63M | -103.93M | -74.09M | -133.45M | -43.46M | -43.75M | -40.84M | -26.42M | -18.82M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -26.74▲ 0% | -2.62▲ 90.2% | -3.81▼ 45.4% | -2.33▲ 38.8% | -3.00▼ 28.8% | -0.95▲ 68.3% | -0.89▲ 6.3% | -1.02▼ 14.6% | -0.53▲ 48.0% | -0.36▲ 0% |
EPS Growth % | -130.52% | 90.2% | -45.42% | 38.85% | -28.76% | 68.33% | 6.32% | -14.61% | 48.04% | 11.2% |
EPS (Basic) | -26.74 | -2.62 | -3.81 | -2.33 | -3.13 | -0.95 | -0.89 | -1.02 | -0.53 | - |
Diluted Shares Outstanding | 2.46M | 27.31M | 27.31M | 31.78M | 43.86M | 45.71M | 48.89M | 49.99M | 50.35M | 52.93M |
Basic Shares Outstanding | 2.46M | 27.31M | 27.31M | 31.78M | 42.49M | 45.71M | 48.89M | 49.99M | 50.35M | 50.75M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
IMCR Balance Sheet
Immunocore Holdings plc (IMCR) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 192.85M | 171.18M | 164.64M | 152.93M | 354.58M | 473.98M | 418.48M | 929.86M | 996.74M | 1B |
Cash & Short-Term Investments | 157.27M | 124.39M | 97.99M | 176.78M | 321.06M | 402.47M | 350.27M | 820.38M | 864.15M | 844.9M |
Cash Only | 111.42M | 124.39M | 97.99M | 176.78M | 321.06M | 402.47M | 350.27M | 455.73M | 467.71M | 452.68M |
Short-Term Investments | 45.84M | 0 | 0 | 0 | 0 | 0 | 0 | 364.64M | 396.44M | 392.22M |
Accounts Receivable | 5.38K | 4.37M | 66.3M | 2.05M | 33.52M | 57.08M | 48.62M | 83.1M | 73.98M | 81.07M |
Days Sales Outstanding | 0.1 | 67.49 | 942.79 | 24.86 | 452.46 | 144.45 | 89.9 | 122.31 | 90.74 | 71.13 |
Inventory | 0 | -7.57M | 0 | -6.51M | 0 | 692K | 3.56M | 5.45M | 6.74M | 8.25M |
Days Inventory Outstanding | - | - | - | - | - | 47.71 | 1.58K | 358.55 | 396.03 | 516.94 |
Other Current Assets | 24.06M | 42.42M | 352.38K | -25.9M | -7.69M | 3.62M | 7.68M | 7.9M | 51.87M | 69.59M |
Total Non-Current Assets | 69.88M | 24.6M | 81.3M | 44.26M | 52.7M | 52.78M | 53.96M | 79.64M | 70.53M | 68.29M |
Property, Plant & Equipment | 32.16M | 20.87M | 72.7M | 36.85M | 42.56M | 38.78M | 33.82M | 47.73M | 50.24M | 49.67M |
Fixed Asset Turnover | 0.60x | 1.13x | 0.35x | 0.82x | 0.64x | 3.72x | 5.84x | 5.20x | 5.92x | 7.80x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 985.41K | 318K | 0 | 0 | 0 | 410 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 973K | 222.69K | 137K | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 36.74M | 2.53M | 6.6M | 4.21M | 6.44M | 8.75M | 11.45M | 17.12M | 20.28M | 18.61M |
Total Assets | 262.73M▲ 0% | 195.78M▼ 25.5% | 245.94M▲ 25.6% | 197.19M▼ 19.8% | 407.28M▲ 106.5% | 526.76M▲ 29.3% | 472.44M▼ 10.3% | 1.01B▲ 113.7% | 1.07B▲ 5.7% | 1.07B▲ 0% |
Asset Turnover | 0.07x | 0.12x | 0.10x | 0.15x | 0.07x | 0.27x | 0.42x | 0.25x | 0.28x | 0.36x |
Asset Growth % | -2.33% | -25.48% | 25.62% | -19.82% | 106.54% | 29.34% | -10.31% | 113.68% | 5.72% | 17.42% |
Total Current Liabilities | 40M | 49.61M | 111.96M | 55M | 82.57M | 100.83M | 110.01M | 212.18M | 246.7M | 240.11M |
Accounts Payable | 10.81M | 6.44M | 20.84M | 7.88M | 10.12M | 14.45M | 14.08M | 25.1M | 24.36M | 30.16M |
Days Payables Outstanding | - | - | 76.06 | 38.45 | - | 996.23 | 6.26K | 1.65K | 1.43K | 2.01K |
Short-Term Debt | 0 | 0 | 27.96M | 9.84M | 0 | 0 | 0 | 0 | 2.01M | 2M |
Deferred Revenue (Current) | 0 | 0 | 37.78M | 27.12M | 33M | 7.76M | 0 | 0 | 583K | 2.33M |
Other Current Liabilities | 20.78M | 29.91M | 25.28M | -19.8M | 83.68K | 9.15M | 9.18M | 13.1M | 219.74M | 207.39M |
Current Ratio | 4.82x | 3.45x | 1.47x | 2.78x | 4.29x | 4.70x | 3.80x | 4.38x | 4.04x | 4.18x |
Quick Ratio | 4.82x | 3.60x | 1.47x | 2.90x | 4.29x | 4.69x | 3.77x | 4.36x | 4.01x | 4.15x |
Cash Conversion Cycle | - | - | - | - | - | -804.07 | -4.59K | -1.17K | -944.39 | -1.42K |
Total Non-Current Liabilities | 40.25M | 89.59M | 114.41M | 86.85M | 93.19M | 87.02M | 70.54M | 436.61M | 439.54M | 438.31M |
Long-Term Debt | 22.77M | 18.88M | 0 | 36.65M | 50.24M | 47.81M | 37.99M | 391.01M | 41.56M | 40.03M |
Capital Lease Obligations | 0 | 0 | 50.74M | 25.19M | 34.22M | 31.76M | 27.41M | 40.16M | 0 | 42.56M |
Deferred Tax Liabilities | 0 | 0 | 0 | -24.87M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 17.48M | 70.71M | 139.1K | 25.01M | 76.93K | 2.21M | 773.94K | 0 | 397.98M | 398.28M |
Total Liabilities | 80.25M | 139.19M | 226.37M | 141.85M | 175.76M | 187.86M | 180.55M | 648.79M | 686.24M | 678.42M |
Total Debt | 22.77M | 18.88M | 78.7M | 74.47M | 86.16M | 81.45M | 66.5M | 432.72M | 43.56M | 42.02M |
Net Debt | -88.65M | -105.51M | -19.29M | -102.31M | -234.9M | -321.02M | -283.77M | -23.01M | -424.15M | -410.65M |
Debt / Equity | 0.12x | 0.33x | 4.02x | 1.35x | 0.37x | 0.24x | 0.23x | 1.20x | 0.11x | 0.11x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.55x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 15.12x |
Interest Coverage | - | -110.99x | -31.17x | -28.57x | -23.18x | -7.91x | -10.81x | -2.22x | -0.17x | -0.85x |
Total Equity | 182.48M▲ 0% | 56.58M▼ 69.0% | 19.57M▼ 65.4% | 55.35M▲ 182.8% | 231.53M▲ 318.3% | 338.9M▲ 46.4% | 291.89M▼ 13.9% | 360.72M▲ 23.6% | 381.03M▲ 5.6% | 393.67M▲ 0% |
Equity Growth % | -15.07% | -68.99% | -65.42% | 182.84% | 318.32% | 46.38% | -13.87% | 23.58% | 5.63% | 22.78% |
Book Value per Share | 74.20 | 2.07 | 0.72 | 1.74 | 5.28 | 7.41 | 5.97 | 7.22 | 7.57 | 7.44 |
Total Shareholders' Equity | 182.48M | 56.58M | 19.57M | 55.35M | 231.53M | 338.9M | 291.89M | 360.72M | 381.03M | 393.67M |
Common Stock | 0 | 0 | 0 | 64K | 118.77K | 129K | 83.18K | 135K | 136K | 137K |
Retained Earnings | -147.9M | -175.18M | -369.75M | -349.87M | -649.7M | -689.39M | -589.3M | -795.76M | -831.27M | -818.3M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 29.27M | 67K | 14.08M | 405.15M | 521.31M | -54.67M | -28.7M | -33.76M | -28.08M | -35.37M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IMCR Cash Flow Statement
Immunocore Holdings plc (IMCR) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -81.9M | -16.63M | -101.38M | -60.57M | -143.11M | -49.21M | 2.33M | 26.06M | -7.97M | -24.9M |
Operating CF Margin % | -427.33% | -70.29% | -394.94% | -201.15% | -529.15% | -34.12% | 1.18% | 10.51% | -2.68% | - |
Operating CF Growth % | -80.77% | 79.7% | -509.74% | 40.25% | -136.25% | 65.61% | 104.73% | 1020.14% | -130.58% | -3505.92% |
Net Income | -65.76M | -71.63M | -103.93M | -74.09M | -180.03M | -52.54M | -34.32M | -51.09M | -26.42M | -18.82M |
Depreciation & Amortization | 5.51M | 6.71M | 9.21M | 8.98M | 7.59M | 5.33M | 3.24M | 4.2M | 2.43M | 3.36M |
Stock-Based Compensation | 4.33M | 666K | 3.06M | 8.16M | 48.89M | 32.89M | 25.69M | 34.19M | 0 | 28.21M |
Deferred Taxes | 0 | -16.55M | -22.26M | -13.27M | -12.69M | -3.53M | 0 | 0 | 11M | 14.79M |
Other Non-Cash Items | -3.89M | -3.4M | 22.64M | 38.45M | 15.09M | -7.19M | 3.14M | -6.38M | 11.94M | -19.06M |
Working Capital Changes | -22.09M | 67.58M | -10.09M | -28.8M | -21.96M | -24.16M | 4.58M | 45.13M | -6.92M | -24.61M |
Change in Receivables | -8.62M | 0 | 1.83M | -532K | -4.86M | -26.26M | -14.14M | -12.35M | -5.46M | -16.59M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 0 | 1.47M | 4.91M | 2.08M | 7.27M | -1.83M | -193.53K |
Cash from Investing | -12.92M | 58.01M | -4.14M | 467K | -1.28M | -2.2M | -4.29M | -355.13M | -12.16M | -21.83M |
Capital Expenditures | -23.52M | -3.54M | -4.28M | -3.07M | -1.39M | -2.2M | -3.37M | -5.17M | -3.23M | -5.82M |
CapEx % of Revenue | 122.72% | 14.95% | 16.66% | 10.21% | 5.12% | 1.53% | 1.71% | 2.09% | 1.08% | 1.51% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 10.6M | 34.1M | 139K | 3.54M | 106K | 6K | -925.46K | 44K | 0 | -1 |
Cash from Financing | 25.64M | 101K | 55.13M | 115.94M | 288.19M | 145.44M | 27.18M | 343.88M | 9.2M | 10.47M |
Debt Issued (Net) | 24.89M | 0 | -4.04M | 45.13M | 0 | 0 | 0 | 352.5M | 0 | 0 |
Equity Issued (Net) | 0 | 0 | 59.87M | 113.41M | 286.89M | 139.51M | 0 | 0 | 9.2M | 7.55M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 744.77K | 101K | -711K | -42.6M | 1.3M | 5.93M | 27.18M | -8.62M | 0 | 2.93M |
Net Change in Cash | -69.19M▲ 0% | 41.5M▲ 160.0% | -50.42M▼ 221.5% | 55.75M▲ 210.6% | 144.42M▲ 159.1% | 81.39M▼ 43.6% | 31.78M▼ 61.0% | 13.11M▼ 58.8% | 8.89M▼ 32.2% | -24.17M▲ 0% |
Free Cash Flow | -105.42M▲ 0% | -20.16M▲ 80.9% | -105.65M▼ 424.0% | -63.65M▲ 39.8% | -144.49M▼ 127.0% | -51.41M▲ 64.4% | -1.97M▲ 96.2% | 20.89M▲ 1162.2% | -11.2M▼ 153.6% | -30.72M▲ 0% |
FCF Margin % | -550.05% | -85.24% | -411.59% | -211.36% | -534.27% | -35.64% | -1% | 8.42% | -3.76% | -7.96% |
FCF Growth % | -99.29% | 80.87% | -423.99% | 39.76% | -127.02% | 64.42% | 96.17% | 1162.18% | -153.61% | -217.95% |
FCF per Share | -42.86 | -0.74 | -3.87 | -2.00 | -3.29 | -1.12 | -0.04 | 0.42 | -0.22 | -0.58 |
FCF Conversion (FCF/Net Income) | 1.25x | 0.23x | 0.98x | 0.82x | 1.07x | 1.13x | -0.05x | -0.64x | 0.30x | 1.63x |
Interest Paid | 0 | 0 | 0 | 0 | 5.71M | 4.48M | 0 | 0 | 10.06M | 5.03M |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 765K | 977K | 510K | 4.64M | 4.61M |
IMCR Key Ratios
Immunocore Holdings plc (IMCR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -33.1% | -59.93% | -272.96% | -197.81% | -93.04% | -15.24% | -13.87% | -12.51% | -7.12% | -4.83% |
Return on Invested Capital (ROIC) | -94.7% | -312.18% | -31597.28% | - | - | -442.43% | -272.43% | -24.41% | -17.18% | -40.34% |
Gross Margin | 100% | 100% | -289.54% | -148.42% | 100% | 96.33% | 99.58% | 97.76% | 97.91% | 98.81% |
Net Margin | -343.13% | -302.82% | -404.89% | -246.04% | -493.45% | -30.13% | -22.17% | -16.45% | -8.88% | -4.88% |
Debt / Equity | 0.12x | 0.33x | 4.02x | 1.35x | 0.37x | 0.24x | 0.23x | 1.20x | 0.11x | 0.11x |
Interest Coverage | - | -110.99x | -31.17x | -28.57x | -23.18x | -7.91x | -10.81x | -2.22x | -0.17x | -0.85x |
FCF Conversion | 1.25x | 0.23x | 0.98x | 0.82x | 1.07x | 1.13x | -0.05x | -0.64x | 0.30x | 1.63x |
Revenue Growth | -5.19% | 23.42% | 8.52% | 17.32% | -10.19% | 433.32% | 36.85% | 25.63% | 20% | 15.64% |
Related:IMCR Dividend History·IMCR Revenue History·IMCR Price History·IMCR P/E History·IMCR Financial Ratios·IMCR Institutional Holders
IMCR SEC Filings & Documents
Immunocore Holdings plc (IMCR) SEC filings — annual & quarterly reports (10-K, 10-Q)
IMCR Frequently Asked Questions
Immunocore Holdings plc (IMCR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Immunocore Holdings plc (IMCR) reported $385.8M in revenue for fiscal year 2025. This represents a 11585% increase from $3.3M in 2013.
Immunocore Holdings plc (IMCR) grew revenue by 20.0% over the past year. This is strong growth.
Immunocore Holdings plc (IMCR) reported a net loss of $18.8M for fiscal year 2025.
Dividend & Returns
Immunocore Holdings plc (IMCR) has a return on equity (ROE) of -7.1%. Negative ROE indicates the company is unprofitable.
Immunocore Holdings plc (IMCR) had negative free cash flow of $30.7M in fiscal year 2025, likely due to heavy capital investments.